Scribe Therapeutics Inc. filed its Form S-1 with the SEC on July 2, 2026, seeking to list on the Nasdaq Global Market under the ticker "SCTX." The Alameda, California-based clinical-stage biotech was co-founded by Dr. Jennifer Doudna, the Nobel laureate whose foundational discovery of CRISPR-based genome editing helped launch the entire gene-editing industry, alongside CEO Benjamin L. Oakes, Ph.D.
Scribe's pitch is a deliberate departure from most CRISPR programs to date: rather than targeting rare, single-gene disorders affecting small patient populations, the company is engineering what it calls "purpose-built in vivo CRISPR technologies" aimed at common diseases affecting millions, starting with the drivers of atherosclerotic cardiovascular disease (ASCVD). Its lead candidate, STX-1150, uses a proprietary epigenetic-silencing technology called ELXR to deliver persistent LDL-cholesterol reductions without making permanent changes to a patient's genome -- a distinction the company argues makes the therapy more tolerable to regulators and patients than earlier, irreversible gene-editing approaches. The company has secured clearance from Australia's Therapeutic Goods Administration and initiated a first-in-human trial of STX-1150 in up to 64 adults with elevated LDL-C, with initial safety and efficacy data expected in the first half of 2027.
The scale of the target market is central to Scribe's pitch: the American Heart Association estimates heart disease costs the US more than $400 billion annually, with someone suffering a heart attack every 40 seconds, and the company argues existing cardiovascular drugs fail broad swaths of patients due to poor long-term adherence, side effects, and treatment that typically begins only after substantial arterial damage has already occurred. Scribe's proprietary "CRISPR by Design" approach combines generative AI and machine learning with high-throughput experimental validation to engineer editing systems tailored to each specific therapeutic application, and the company has additional candidates, STX-1200 and STX-1400, moving through its pipeline behind STX-1150.
“The offering is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities.”
The financial picture disclosed in the filing is stark. As of March 31, 2026, Scribe had just $49.7 million in cash, cash equivalents and marketable securities against an accumulated deficit of $175.1 million, having posted a $17.4 million net loss in the first quarter of 2026 alone. The company states directly that, based on capital resources on hand, it will not have sufficient cash to support operations for at least twelve months without the proceeds of this offering -- a going-concern disclosure that puts real urgency behind the IPO succeeding, rather than functioning as a purely opportunistic capital-markets exercise. Since its 2017 founding, the company has raised approximately $150 million in equity financing, notably with only one dilutive financing round in the past four years, a detail the company highlights as evidence of disciplined capital management up to this point. The offering is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities.
The broader context matters here: Scribe is going public into a biotech IPO market that has been more selective than the AI-infrastructure and frontier-lab financings dominating 2026 headlines, and a going-concern disclosure this explicit is a meaningfully higher-risk profile than most recent biotech listings. At the same time, a Doudna-founded company attempting to move CRISPR technology from rare-disease niches into one of the largest chronic-disease categories in medicine is a genuinely ambitious scientific and commercial bet, one that -- if the Australian trial data reads out well in 2027 -- could reset how investors think about gene editing's addressable market.
For founders and investors in biotech, Scribe's filing is a clean example of a company using an offshore trial (Australia's TGA pathway) to generate early clinical data faster and more cheaply before engaging the FDA directly, a strategy an increasing number of gene-editing and cell-therapy companies have adopted. For LPs evaluating deep-tech and biotech-adjacent venture exposure, the explicit going-concern language attached to a Nobel-laureate-founded company is a reminder that scientific pedigree alone doesn't eliminate real capital-adequacy risk heading into a public offering.
What to watch: whether Scribe successfully prices and completes its IPO given the going-concern disclosure, how the market responds to a CRISPR company targeting a common chronic disease rather than a rare genetic disorder, and whether the Australian STX-1150 trial data expected in the first half of 2027 validates the company's epigenetic-silencing approach to cardiovascular risk reduction.